Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 24, 2025 09:56 ET | Source: Bavarian Nordic A/S

Rumours of a Potential Takeover Offer for Bavarian Nordic A/S

COPENHAGEN, Denmark, July 24, 2025 – Bavarian Nordic A/S (OMX: BAVA) has become aware of market rumours regarding a potential takeover offer for Bavarian Nordic A/S by a consortium consisting of...
July 24, 2025 09:56 ET | Source: Bavarian Nordic A/S

Rumours of a Potential Takeover Offer for Bavarian Nordic A/S

COPENHAGEN, Denmark, July 24, 2025 – Bavarian Nordic A/S (OMX: BAVA) has become aware of market rumours regarding a potential takeover offer for Bavarian Nordic A/S by a consortium consisting of...
July 22, 2025 02:00 ET | Source: Bavarian Nordic A/S

Bavarian Nordics ansøgning om markedsføringstilladelse for chikungunyavaccinen er blevet accepteret til gennemgang af de canadiske lægemiddelmyndigheder

KØBENHAVN, Danmark, 22. juli 2025 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag, at de canadiske lægemiddelmyndigheder, Health Canada, har accepteret selskabets ansøgning om...
July 22, 2025 02:00 ET | Source: Bavarian Nordic A/S

Bavarian Nordic Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya Vaccine

COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose,...
July 09, 2025 10:46 ET | Source: Bavarian Nordic A/S

Bavarian Nordic modtager ny ordre på koppe-/mpoxvacciner fra europæisk land

Gentagen ordre fra unavngivet europæisk land til styrkelse af det offentlige beredskab.Sammen med andre nylige ordrer fra ikke-europæiske lande har selskabet nu sikret kontrakter for mere end DKK...
July 09, 2025 10:46 ET | Source: Bavarian Nordic A/S

Bavarian Nordic Enters New Smallpox/Mpox Vaccine Supply Contract with European Country

Recurring order from an undisclosed European country to strengthen public preparedness.Combined with other recent orders from non-European countries, the Company has now secured above DKK 3,000...
June 26, 2025 02:00 ET | Source: Bavarian Nordic A/S

Kliniske forsøg med Bavarian Nordics mpox-vaccine er påbegyndt i spædbørn og gravide kvinder

Forsøgene er de første, der evaluerer MVA-BN hos spædbørn under 2 år samt gravide og ammende kvinder.Forskningsprojekt har til formål at udvide adgangen til mpox-vacciner for sårbare...
June 26, 2025 02:00 ET | Source: Bavarian Nordic A/S

Bavarian Nordic Announces the Initiation of Clinical Trials of Mpox Vaccine in Infants and Pregnant Women

First studies to evaluate MVA-BN in infants under 2 years of age and pregnant and breastfeeding women.The multi-partner research project is aimed at expanding access to mpox vaccines for vulnerable...
June 18, 2025 03:04 ET | Source: Bavarian Nordic A/S

Bavarian Nordic sælger Priority Review Voucher for USD 160 mio.

KØBENHAVN, Danmark, 18. juni 2025 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har indgået aftale om salg af sin Priority Review Voucher (PRV) for USD 160 mio. kontant. Bavarian...
June 18, 2025 03:04 ET | Source: Bavarian Nordic A/S

Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 Million

COPENHAGEN, Denmark, June 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher (PRV) for a total cash consideration of...